15 years of historical data (2011–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Agios Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.25T | $1.6B | $1.9B | $1.2B | $1.5B | $2.0B | $3.0B | $2.9B | $2.6B | $2.7B | $1.6B |
| Enterprise Value | $2.25T | $1.5B | $1.9B | $1.2B | $1.5B | $1.9B | $3.0B | $2.9B | $1.8B | $2.1B | $1.1B |
| P/E Ratio → | -4.25 | — | 2.82 | — | — | — | — | — | — | — | — |
| P/S Ratio | 9999.00 | 29.21 | 52.12 | 46.21 | 108.04 | — | — | 24.30 | 28.05 | 61.92 | 23.36 |
| P/B Ratio | 1.47 | 1.32 | 1.23 | 1.53 | 1.40 | 1.54 | 7.48 | 4.47 | 3.85 | 7.09 | 4.55 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 57.00 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 42.34 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 28.30 | 51.59 | 45.60 | 104.28 | — | — | 24.57 | 19.52 | 48.72 | 15.15 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 36.97 |
Margins and return-on-capital ratios measuring operating efficiency
Agios Pharmaceuticals, Inc. earns an operating margin of -873.9%. Operating margins have expanded from -1459.5% to -873.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -30.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | 88.3% | 88.6% | 64.6% | 88.0% | — | — | 98.9% | 98.5% | -580.5% | -215.0% |
| Operating Margin | -873.9% | -873.9% | -1166.5% | -1459.5% | -2732.1% | — | — | -361.6% | -384.0% | -745.8% | -287.6% |
| Net Profit Margin | -764.0% | -764.0% | 1845.9% | -1312.6% | -1627.8% | — | — | -349.0% | -366.6% | -731.6% | -284.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -30.2% | 57.3% | -36.8% | -19.4% | 189.7% | -63.0% | -62.0% | -65.1% | -85.7% | -56.4% |
| ROA | -27.9% | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% |
| ROIC | -26.6% | -26.6% | -27.6% | -31.9% | -26.1% | -36.3% | -48.0% | -115.1% | — | — | — |
| ROCE | -33.8% | -33.8% | -34.7% | -38.3% | -30.5% | -35.4% | -43.2% | -54.6% | -56.4% | -61.1% | -44.8% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $89M exceeds total debt of $40M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.09 | 0.08 | 0.08 | 0.26 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.01 | -0.02 | -0.05 | -0.08 | -0.06 | 0.05 | -1.17 | -1.51 | -1.60 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -20.02 |
| Interest Coverage | — | — | — | — | — | — | -18.84 | — | — | — | — |
Net cash position: cash ($89M) exceeds total debt ($40M)
Short-term solvency ratios and asset-utilisation metrics
Agios Pharmaceuticals, Inc.'s current ratio of 11.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 11.06x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 12.27x to 11.46x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.46 | 11.46 | 11.90 | 12.27 | 13.30 | 17.79 | 6.74 | 6.59 | 6.56 | 4.69 | 6.33 |
| Quick Ratio | 11.06 | 11.06 | 11.56 | 11.99 | 13.16 | 17.79 | 6.74 | 6.51 | 6.55 | 6.20 | 6.70 |
| Cash Ratio | 10.39 | 10.39 | 11.01 | 11.43 | 12.50 | 17.05 | 6.07 | 6.08 | 8.61 | 5.98 | 6.49 |
| Asset Turnover | — | 0.04 | 0.02 | 0.03 | 0.01 | — | — | 0.13 | 0.11 | 0.07 | 0.11 |
| Inventory Turnover | 0.19 | 0.19 | 0.15 | 0.50 | 0.20 | — | — | 0.18 | 1.61 | — | — |
| Days Sales Outstanding | — | 71.46 | 41.09 | 38.24 | 56.54 | — | — | 47.42 | 40.38 | 31.14 | 43.42 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Agios Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 35.4% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 1.8% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 40.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $58M | $58M | $56M | $55M | $60M | $69M | $60M | $57M | $47M | $39M |
Compare AGIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| AGIOYou | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how AGIO stacks up against sector leader Vertex Pharmaceuticals Incorporated.
Start ComparisonAgios Pharmaceuticals, Inc.'s current P/E ratio is -4.2x. The historical average is 2.8x.
Agios Pharmaceuticals, Inc.'s return on equity (ROE) is -30.2%. The historical average is -22.8%.
Based on historical data, Agios Pharmaceuticals, Inc. is trading at a P/E of -4.2x. Compare with industry peers and growth rates for a complete picture.
Agios Pharmaceuticals, Inc. has 88.3% gross margin and -873.9% operating margin.